OTCMKTS:IPATF ImmunoPrecise Antibodies (IPATF) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free IPATF Stock Alerts $1.19 -0.03 (-2.45%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.17▼$1.2550-Day Range$1.22▼$1.9852-Week Range$1.15▼$20.25Volume127,944 shsAverage Volume20,327 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get ImmunoPrecise Antibodies alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About ImmunoPrecise Antibodies Stock (OTCMKTS:IPATF)ImmunoPrecise Antibodies Ltd. engages in the provision of human therapeutic antibody discovery and development services. It offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.Read More IPATF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPATF Stock News HeadlinesApril 17, 2024 | americanbankingnews.comImmunoPrecise Antibodies (OTCMKTS:IPATF) Trading Up 4%March 28, 2024 | benzinga.comEXCLUSIVE: Immunoprecise Antibodies and InterSystems Integrate Vector Search With LENSai For AI-Driven Healthcare ApplicationsApril 26, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…February 12, 2024 | benzinga.comImmunoPrecise Antibodies (NASDAQ: IPA) Is Changing How We Look At The Complex World Of Antibody DiscoveryMarch 17, 2023 | stockhouse.comImmunoPrecise Antibodies' Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera BioSeptember 15, 2022 | seekingalpha.comImmunoPrecise Antibodies reports FQ1 resultsSee More Headlines Receive IPATF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IPATF CUSIPN/A CIKN/A Webwww.immunoprecise.com Phone(250) 483-0308FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesJennifer BathPresident, Chief Executive Officer & DirectorLisa HelblingChief Financial OfficerYasmina Noubia AbdicheChief Scientific OfficerStefan LangChief Business OfficerKari GraberVP-Client Relations & Project ManagementKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors IPATF Stock Analysis - Frequently Asked Questions How have IPATF shares performed in 2024? ImmunoPrecise Antibodies' stock was trading at $1.71 on January 1st, 2024. Since then, IPATF shares have decreased by 30.2% and is now trading at $1.1940. View the best growth stocks for 2024 here. How do I buy shares of ImmunoPrecise Antibodies? Shares of IPATF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IPATF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.